COMMUNIQUÉS West-GlobeNewswire

Veraify Launches Groundbreaking AI-Native Security Platform Built for the AI Workforce Era
22/07/2026
New Platform Puts Enterprises in the AI Drivers Seat, with More Control over Shadow AI, AI Workforce, and Sensitive Data Movement, Securing AI Adoption Without Slowing Innovation SUNNYVALE, Calif., July 22, 2026 (GLOBE [...]
Cannara Announces Normal Course Issuer Bid
22/07/2026
MONTREAL, July 22, 2026 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (“ Cannara ”, the “ Company ”, “ us ” or “ we ”) ( TSX: LOVE ) ( OTCQX: LOVFF ) ( FRA: 8CB0 ),a vertically integrated producer of premium-grade cannabis [...]
Cannara annonce une offre publique de rachat dans le cours normal des activités
22/07/2026
MONTRÉAL, 22 juill. 2026 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (« Cannara », « la Société », « nous ») ( TSX : LOVE ) ( OTCQX : LOVFF ) ( FRA : 8CB0 ), producteur verticalement intégré de cannabis de qualité [...]
KC BioHub Awarded $38.1 Million to Advance Regional Biomanufacturing Growth
22/07/2026
Federally recognized Tech Hub positioned to unlock a total of $150 million in federal investment KANSAS CITY, Mo., July 22, 2026 (GLOBE NEWSWIRE) -- The KC BioHub, a program of BioNexus KC , with partners MRIGlobal and [...]
VisiRose Selected to Present RB-PDAT at ESCRS iNovation® Day 2026 Emerging Company Showcase
22/07/2026
KNOXVILLE, Tenn., July 22, 2026 (GLOBE NEWSWIRE) -- VisiRose, Inc. (“VisiRose” or the “Company”), the clinical-stage ophthalmology subsidiary of Provectus Biopharmaceuticals, Inc. (“Provectus”) (OTCQB: PVCT), a clinical [...]
Zevra Therapeutics Announces Details for Q2 2026 Financial Results Call
22/07/2026
BOSTON, Mass., July 22, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare [...]
BridgeBio Announces FDA Acceptance of NDA for Encaleret for ADH1
22/07/2026
- PDUFA target action date of May 8, 2027 - If approved, encaleret will be the first and only approved therapy specifically indicated for individuals living with ADH1 , representing a potential blockbuster opportunity [...]
Trinity Biotech Partners with Latch Medical to Advance Biosensor-Guided Precision Drug Delivery Solutions Using CGM+ Technology
22/07/2026
- Strategic collaboration and equity investment will combine Trinity Biotech's AI-native CGM+ wearable biosensor platform with Latch Medical's innovative intradermal drug delivery technology to develop next-generation [...]
Lungpacer Announces New Category III CPT® Codes for AeroPace® Diaphragm Neurostimulation Therapy
22/07/2026
New AMA Category III codes, effective July 1, 2026, support the development of future reimbursement pathways for temporary transvenous diaphragm neurostimulation EXTON, Pa., July 22, 2026 (GLOBE NEWSWIRE) -- Lungpacer [...]
Tiziana Life Sciences Announces Purchase of Shares by Executive Chairman
22/07/2026
BOSTON, July 22, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development [...]
Publication in Clinical Reviews in Allergy & Immunology Summarizes Decades of Evidence Supporting Bradykinin B2 Receptor as a Validated Therapeutic Target in Bradykinin-Mediated Angioedema
22/07/2026
Provides a state-of-the-art overview of the evidence on the critical role of bradykinin B2 receptor in the pathogenesis of bradykinin-mediated angioedema Explains the scientific foundation for targeting the bradykinin [...]
Biodesix to Report Second Quarter 2026 Financial Results on August 5, 2026
22/07/2026
LOUISVILLE, Colo., July 22, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the second quarter ended June 30, [...]
RadNet, Inc. Announces Date of its Second Quarter 2026 Financial Results Conference Call
22/07/2026
LOS ANGELES, July 22, 2026 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT) , a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of owned and operated outpatient [...]
Repligen to Acquire BioLife Solutions, Expanding Its Cell Therapy Capabilities with Market Leading Biopreservation Media
22/07/2026
Fast-tracks Repligen’s leadership and customer solution offering in high-growth cell therapy market by adding BioLife’s differentiated, high-margin recurring revenue business BioLife stockholders to receive cash and [...]
Greenwich LifeSciences Announces Approval to Expand FLAMINGO-01 into the United Kingdom
22/07/2026
STAFFORD, Texas, July 22, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is [...]
Acentra Health Appoints Sreedevi Hegde as Senior Vice President – India Country Head
22/07/2026
Seasoned global business leader to drive the growth of Acentra Health's India organization and accelerate the company's transformation journey MCLEAN, Va., July 22, 2026 (GLOBE NEWSWIRE) -- Acentra Health , a technology [...]
Trinity Biotech Plc Announces Plan to Implement ADS Ratio Change
22/07/2026
DUBLIN, July 22, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), (the “Company”) today announced that it plans to change the ratio of the American depositary shares (“ADSs”) representing its Class A [...]
uniQure to Announce Second Quarter 2026 Financial Results
22/07/2026
~ uniQure to host earnings call on Wednesday, July 29, 2026 at 8:30 a.m. ET ~ LEXINGTON, Mass. and AMSTERDAM, July 22, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing [...]
Radiopharm Theranostics Achieves Confirmed Durable Partial Response in Ongoing Phase 1 Trial of RAD204 in Patients with Advanced Solid Tumors Post-Immunotherapy
22/07/2026
First RECIST-confirmed durable Partial Response at current highest dose level #3 (90mCi) with the patient remaining progression free beyond seven months Second patient dosed remains progression free on treatment with [...]

Pages